Tags

Type your tag names separated by a space and hit enter

[New drugs; rimonabant].
Ned Tijdschr Geneeskd. 2007 Nov 24; 151(47):2620-2.NT

Abstract

The endocannabinoid system controls the regulation of food intake and appetite in the brain and lipogenesis in adipose tissue. Rimonabant belongs to the new drug class of cannabinoid-1 receptor antagonists. It can decrease appetite and food intake and thus stimulate weight loss. Rimonabant is indicated for severe obesity and as an adjunct to lifestyle modifications for obese patients with type 2 diabetes or hyperlipidaemia. Safety concerns limit the clinical applicability of the drug. The drug has not been approved in the US due to its neurological and psychiatric adverse effects. Rimonabant is approved in Europe but is contraindicated in patients with major depression and those taking antidepressants.

Authors+Show Affiliations

Leids Universitair Medisch Centrum, Leiden.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

dut

PubMed ID

18161263

Citation

van Bronswijk, H, et al. "[New Drugs; Rimonabant]." Nederlands Tijdschrift Voor Geneeskunde, vol. 151, no. 47, 2007, pp. 2620-2.
van Bronswijk H, Dubois EA, Pijl H, et al. [New drugs; rimonabant]. Ned Tijdschr Geneeskd. 2007;151(47):2620-2.
van Bronswijk, H., Dubois, E. A., Pijl, H., & Cohen, A. F. (2007). [New drugs; rimonabant]. Nederlands Tijdschrift Voor Geneeskunde, 151(47), 2620-2.
van Bronswijk H, et al. [New Drugs; Rimonabant]. Ned Tijdschr Geneeskd. 2007 Nov 24;151(47):2620-2. PubMed PMID: 18161263.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [New drugs; rimonabant]. AU - van Bronswijk,H, AU - Dubois,E A, AU - Pijl,H, AU - Cohen,A F, PY - 2007/12/29/pubmed PY - 2008/1/30/medline PY - 2007/12/29/entrez SP - 2620 EP - 2 JF - Nederlands tijdschrift voor geneeskunde JO - Ned Tijdschr Geneeskd VL - 151 IS - 47 N2 - The endocannabinoid system controls the regulation of food intake and appetite in the brain and lipogenesis in adipose tissue. Rimonabant belongs to the new drug class of cannabinoid-1 receptor antagonists. It can decrease appetite and food intake and thus stimulate weight loss. Rimonabant is indicated for severe obesity and as an adjunct to lifestyle modifications for obese patients with type 2 diabetes or hyperlipidaemia. Safety concerns limit the clinical applicability of the drug. The drug has not been approved in the US due to its neurological and psychiatric adverse effects. Rimonabant is approved in Europe but is contraindicated in patients with major depression and those taking antidepressants. SN - 0028-2162 UR - https://www.unboundmedicine.com/medline/citation/18161263/[New_drugs L2 - https://medlineplus.gov/obesity.html DB - PRIME DP - Unbound Medicine ER -